

Journal Pre-proof

Fully Covered Self-Expanding Metal Stent versus Multiple Plastic Stents to Treat Benign Biliary Strictures Secondary to Chronic Pancreatitis: A Multicenter Randomized Trial

Mohan Ramchandani, MD, DM, Sundeep Lakhtakia, MD, DM, Guido Costamagna, MD, Andrea Tringali, MD, PhD, Andreas Püspöek, MD, Barbara Tribl, MD, Werner Dolak, MD, Jacques Devière, MD, PhD, Marianna Arvanitakis, MD, PhD, Schalk van der Merwe, MD, PhD, Wim Laleman, MD, PhD, Thierry Ponchon, MD, PhD, Vincent Lepilliez, MD, Armando Gabbrielli, MD, Laura Bernardoni, MD, Marco J. Bruno, MD, PhD, Jan-Werner Poley, MD, PhD, Urban Arnelo, MD, PhD, James Lau, MD, André Roy, MD, Michael Bourke, MD, Arthur Kaffes, MD, Horst Neuhaus, MD, PhD, Joyce Peetermans, PhD, Matthew Rousseau, Nageshwar Reddy, MD, DM

PII: S0016-5085(21)00522-9
DOI: <https://doi.org/10.1053/j.gastro.2021.03.015>
Reference: YGAST 64206

To appear in: *Gastroenterology*
Accepted Date: 6 March 2021

Please cite this article as: Ramchandani M, Lakhtakia S, Costamagna G, Tringali A, Püspöek A, Tribl B, Dolak W, Devière J, Arvanitakis M, van der Merwe S, Laleman W, Ponchon T, Lepilliez V, Gabbrielli A, Bernardoni L, Bruno MJ, Poley J-W, Arnelo U, Lau J, Roy A, Bourke M, Kaffes A, Neuhaus H, Peetermans J, Rousseau M, Reddy N, Fully Covered Self-Expanding Metal Stent versus Multiple Plastic Stents to Treat Benign Biliary Strictures Secondary to Chronic Pancreatitis: A Multicenter Randomized Trial, *Gastroenterology* (2021), doi: <https://doi.org/10.1053/j.gastro.2021.03.015>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2021 by the AGA Institute





RCT of MPS versus FCSEMS to treat benign biliary strictures in chronic pancreatitis

Randomization


84 to multiple plastic stents

80 to fully covered self-expanding metal stent

12-month treatment



12-month follow-up



Gastroenterology

Fully Covered Self-Expanding Metal Stent versus Multiple Plastic Stents to Treat Benign Biliary Strictures Secondary to Chronic Pancreatitis: A Multicenter Randomized Trial

Short title: FCSEMS versus MPS for benign biliary strictures in chronic pancreatitis RCT

Mohan Ramchandani, MD, DM¹

Sundeep Lakhtakia, MD, DM¹

Guido Costamagna, MD^{2,3}

Andrea Tringali, MD, PhD^{2,3}

Andreas Püspöck, MD⁴

Barbara Tribl, MD⁵

Werner Dolak, MD⁵

Jacques Devière, MD, PhD⁶

Marianna Arvanitakis, MD, PhD⁶

Schalk van der Merwe, MD, PhD⁷

Wim Laleman, MD, PhD⁷

Thierry Ponchon, MD, PhD⁸

Vincent Lepilliez, MD⁸

Armando Gabbrielli, MD⁹

Laura Bernardoni, MD⁹

Marco J. Bruno, MD, PhD¹⁰

Jan-Werner Poley, MD, PhD¹⁰

Urban Arnelo, MD, PhD¹¹

James Lau, MD¹²

André Roy, MD¹³

Michael Bourke, MD¹⁴

Arthur Kaffes, MD¹⁵

Horst Neuhaus, MD, PhD¹⁶

Joyce Peetermans, PhD¹⁷

Matthew Rousseau¹⁷

Nageshwar Reddy, MD, DM¹

¹Asian Institute of Gastroenterology, Hyderabad, India

²Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; Digestive Endoscopy Unit

³Università Cattolica del Sacro Cuore, Roma, Italia; Centre for Endoscopic Research Therapeutics and Training (CERTT)

⁴St. John's Hospital, Eisenstadt, Austria

⁵Medizinische Universität Wien, Vienna, Austria

⁶Hôpital Erasme, Brussels, Belgium

⁷University Hospitals Leuven, Leuven, Belgium

⁸Hôpital Edouard Herriot, Lyon, France

⁹Università degli Studi Verona Policlinico G.B. Rossi, Verona, Italy

¹⁰Erasmus Medical Center, Rotterdam, The Netherlands

¹¹CLINTEC, Div of Surgery, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden

¹²Prince of Wales Hospital, New Territories, Hong Kong

¹³Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada

¹⁴Western Clinical School, University of Sydney, Westmead Hospital, Sydney, NSW, Australia

¹⁵Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia

¹⁶Evangelisches Krankenhaus Düsseldorf, Düsseldorf, Germany

¹⁷Endoscopy Division, Boston Scientific Corporation, Marlborough, Massachusetts, USA

Grant support: Boston Scientific Corporation

Abbreviations: ASGE American Society for Gastrointestinal Endoscopy; BBS benign biliary stricture; CDM complete distal migration; CI confidence interval; CP chronic pancreatitis; ERCP endoscopic retrograde cholangiopancreatography; ESGE European Society of Gastrointestinal Endoscopy; FCSEMS fully covered self-expanding metal stent; MPS multiple plastic stents; RCT randomized controlled trial; SAE serious adverse event; SAS Statistical Analysis System; SD standard deviation

Correspondence: Dr. D. Nageshwar Reddy, M.D, D.M.; Chairman and Chief of Gastroenterology; Asian Institute of Gastroenterology; (AIG Hospitals); Hyderabad, India; Office phone: +91-40-2337 8888; Fax : +91-40-2332 4255; E-mail: aigindia@yahoo.co.in

Disclosures: These authors disclose the following: G. Costamagna: Grants from Cook Endoscopy, Olympus, and Boston Scientific; member on advisory committees or review panels for Boston Scientific and Olympus. A. Tringali: Consultancy agreements with Boston Scientific. B. Tribl: Consultancy fees from Boston Scientific and AiCuris. W. Dolak: Consultancy fees from Boston Scientific and Norgine. J. Devière: Research support from Boston Scientific, Cook Medical, and Olympus; shareholder in Endotools. M. Arvanitakis: personal fees from Olympus. S. van der Merwe: Grants from Cook Medical and Boston Scientific, speakers fee Olympus, Pentax. W. Laleman: Consultancy agreements with Boston Scientific and Cook Medical. T. Ponchon: Grants from Boston Scientific; personal fees from Olympus, Boston Scientific, Norgine, Fujifilm, Ipsen, and Alfa Sigma. M. Bruno: Research grants from Boston Scientific, Cook Medical, 3M, and Pentax Medical; personal fees from Boston Scientific and Cook Medical. J.W. Poley: Consultant, speaker, and travel expenses from Boston Scientific, Cook Endoscopy, and Pentax. U. Arnelo: Consultancy fees from Boston Scientific. M. Bourke: Research support from Boston Scientific, Cook Medical, and Olympus. A. Kaffes: research grants from Boston, Cook Medical, Medtronic and Olympus. H. Neuhaus: Consultancy agreements with Boston Scientific, Cook Medical, Erbe, Medtronic, Olympus; research support from Boston Scientific, Erbe, Fujifilm, Olympus, Pentax Medical. J. Peetermans, M. Rousseau:

Employee of Boston Scientific. All other authors disclosed no financial relationships relevant to this publication.

Writing assistance: Margaret Gourlay, MD, MPH, a Boston Scientific Corporation employee, provided writing assistance.

Author contributions: MRamchandani, NR: study concept and design, procedure development, acquisition of data, first manuscript draft, interpretation of results, study supervision. SL, GC, AT, AP, BT, WD, JD, MA, SvdM, WL, TP, AG, MBruno, UA, JL, AR, MBourke, AK, HN: acquisition of data, interpretation of results. JP: study concept and design, first manuscript draft, interpretation of results, obtained funding, administrative, technical or material support, study supervision. MRousseau: study concept and design, statistical analysis, first manuscript draft, interpretation of results. All authors provided critical revision of the manuscript and approved the final draft.

Word count: 254 abstract (limit 260), 4616 words (3652 main text; 838 references; 126 table/figure legends) (limit 7000 for main + refs + table/figs)

ABSTRACT

Background & Aims Benign biliary strictures (BBS) are complications of chronic pancreatitis (CP). Endotherapy using multiple plastic stents (MPS) or a fully covered self-expanding metal stent (FCSEMS) are acceptable treatment options for biliary obstructive symptoms in these patients.

Methods Patients with symptomatic CP-associated BBS enrolled in a multicenter randomized noninferiority trial comparing 12-month treatment with MPS versus FCSEMS. Primary outcome was stricture resolution status at 24 months, defined as absence of restenting and 24-month serum alkaline phosphatase not exceeding twice the level at stenting completion. Secondary outcomes included crossover rate, numbers of ERCPs and stents, and stent- or procedure-related serious adverse events (SAEs).

Results Eighty-four patients were randomized to MPS and 80 to FCSEMS. Baseline technical success was 97.6% for MPS and 98.6% for FCSEMS. Eleven patients crossed over from MPS to FCSEMS, and 10 from FCSEMS to MPS. For MPS vs. FCSEMS respectively, stricture resolution status at 24 months was 77.1% (54/70) vs. 75.8% (47/62) ($P=0.008$ for noninferiority ITT analysis), mean number of ERCPs was 3.9 ± 1.3 vs. 2.6 ± 1.3 ($P<0.001$, ITT), and mean number of stents placed was 7.0 ± 4.4 vs. 1.3 ± 0.6 ($P<0.001$, as-treated). SAEs occurred in 16 (19.0%) MPS and 19 (23.8%) FCSEMS patients ($P=0.568$), including cholangitis/fever/jaundice (9 vs. 7 patients respectively), abdominal pain (5 vs. 5), cholecystitis (1 vs. 3) and post-ERCP pancreatitis (0 vs. 2). No stent- or procedure-related deaths occurred.

Conclusions Endotherapy of CP-associated BBS has similar efficacy and safety for 12-month treatment using MPS compared to a single FCSEMS, with FCSEMS requiring fewer ERCPPs over 2 years. (ClinicalTrials.gov, Number: NCT01543256)

Key words: biliary stenting; chronic pancreatitis; plastic stents; randomized trial; self-expandable metallic stents

Journal Pre-proof

BACKGROUND AND AIMS

In advanced chronic pancreatitis (CP), 10% to 30% of patients may develop symptomatic benign biliary stricture (BBS) in which biliary obstruction may lead to jaundice, persistent cholestasis, acute cholangitis and secondary biliary cirrhosis.^{1,2} Benign strictures causing chronic cholestasis, jaundice, and cholangitis deserve treatment in order to avoid secondary biliary cirrhosis and surgery.³ While no treatment is required in asymptomatic patients with CP-associated BBS, biliary drainage is indicated in symptomatic patients. Clinical decision-making is complex for this condition and varies among specialists,⁴ with endotherapy, radiological, surgical and medical treatment as options. Endotherapy using multiple plastic stents (MPS) or a single removable fully covered self-expanding metal stent (FCSEMS) are acceptable options for patients with biliary obstructive symptoms associated with BBS. Long-term results for these treatments have been published in single-arm studies^{5,6} and a randomized controlled trial (RCT) comparing both options.⁷ The published RCT required 6 months of stent treatment, specifically with three 10-Fr plastic stents at randomization and an additional three 10-Fr at 3 months totaling six 10-Fr plastic stents in the MPS arm compared to one 10-mm diameter FCSEMS in the other arm. The need for additional long-term RCT data on endoscopic CP management was highlighted in European Society of Gastrointestinal Endoscopy (ESGE)⁸ and American Society for Gastrointestinal Endoscopy (ASGE)^{9,10} guidelines.

To provide additional good-quality evidence regarding optimal endoscopic management in this patient population, we conducted a randomized noninferiority trial comparing 2-year efficacy and safety outcomes of MPS and FCSEMS to treat BBS in patients with CP. The aim of the trial was to determine whether the 24-month rate of stricture resolution in patients with CP-associated

BBS randomized to 12-month treatment with FCSEMS is noninferior to the rate for patients receiving 12-month treatment with MPS.

METHODS

Study Design

This study was an open label, multicenter, randomized noninferiority clinical trial conducted at 14 centers in 11 countries. The study was approved by the institutional review boards and medical ethics committees of all participating sites, and was registered in the ClinicalTrials.gov database (NCT01543256) on March 2, 2012. Study participation began in September 2012 and ended in September 2020. All participants provided written informed consent before randomization. All authors had access to the study data and reviewed and approved the final manuscript.

Participants

The site investigators screened patients for study eligibility, enrolled participants, and assigned participants to interventions. Eligible patients were aged 18 years or older with documented CP, symptomatic bile duct stricture (defined by cholangitis or persistent jaundice for at least one month or cholestasis associated with at least 3 times normal alkaline phosphatase levels) documented at time of enrollment for naïve stricture or at the time of prior plastic stent placement in strictures that had one prior plastic stent inserted,¹¹ and common bile duct stricture based on imaging assessment of dilatation of the common and/or intrahepatic bile ducts. Excluded were patients with non-CP etiology of BBS or malignant bile duct stricture, a prior biliary metal stent or more than one plastic stent of 10 Fr size or smaller for ≥ 6 months,

developing obstructive biliary symptoms associated with onset of acute pancreatitis, stricture within 2 cm of common bile duct bifurcation, known bile duct fistula or leak, symptomatic duodenal stenosis with gastric stasis, contraindication to endoscopic techniques or devices, participation in another investigational study within 90 days prior to consent, or exclusion by investigator discretion. A cholangiogram or other common bile duct imaging was performed prior to stent placement in all patients.

Randomization

Within each study site, eligible patients were randomized (1:1 allocation ratio using blocks of 4) into 12-month treatment with sequential placement of MPS (any brand) versus one placement of a biliary FCSEMS (Fully Covered WallFlex Biliary Stent, Boston Scientific, Marlboro, MA, USA) (**Figure 1**). Randomization schedules were computer-generated in advance, using a pseudo-random number generator and loaded into the Electronic Data Capture (EDC) system. No member of the study team or anyone else at the study site had access to the random number sequence. Site investigators obtained randomization assignments stratified by clinical site from the EDC system at the time of the procedure. For back-up randomization in cases of unsuccessful EDC access, sites were instructed to randomize subjects via back-up envelopes only. The back-up randomized treatment assignments were kept in sequentially numbered, sealed opaque envelopes.

Multiple Plastic Stents

Participants in the MPS arm had 3 or 4 side-by-side MPS stenting procedures during the 12-month treatment period. The size and number of MPS placed at each procedure was left to the

investigator's discretion. The study protocol stated that "for subjects randomized to PS, at least two 8.5 or 10 Fr. PS should be placed whenever possible." After the index procedure, follow-up visits for assessment of biliary obstructive symptoms and adverse events were conducted at 1 month after stent placement in a clinic or telephone visit, and in clinic or hospital visits at 4 months and 8 months for MPS exchange and serum liver enzyme tests. In these follow-up procedures, clinicians had the option to exchange or increase the number of plastic stents. At 12 months, stent removal, a cholangiogram or other common bile duct imaging, and serum liver enzyme tests were performed. At 24 months, assessment of biliary obstructive symptoms and adverse events, and serum liver enzyme tests were performed. Additional visits were conducted at the investigator's discretion, most typically in cases of an adverse event.

Fully Covered Self-Expanding Metal Stent

The protocol for patients who received a single 8 mm or 10 mm diameter FCSEMS was similar to the MPS arm but excluded the office visits at 4 months and 8 months. The size of the FCSEMS placed at the index procedure was left to the investigator's discretion. The planned FCSEMS indwell period was 12 months.

Study Completion

As described above, each subject was followed for 2 years after initial stent placement, planning for 12 months of active treatment and 12 months of follow-up thereafter. It was possible that recurrent strictures occurring during follow-up were treated with FCSEMS in the MPS group and with MPS in the FCSEMS group. In such cases, the original treatment assignment was maintained in the final analysis of the primary outcome. A subject was considered lost to follow-

up if he/she remained unresponsive to communication after 3 documented attempts by study staff.

Outcomes

The primary clinical outcome was biliary stricture resolution status 24 months after initial stent(s) placement (i.e. 12 months after stent removal), defined as absence of restenting after the stenting period and 24-month serum alkaline phosphatase level not exceeding twice the level at the end of the stenting period. Secondary clinical outcomes included technical success of stent placement, number of endoscopic retrograde cholangiopancreatography (ERCP) procedures during 24 months after initial stent placement, total number of stents placed during the study, duration of stent placement procedure, and total treatment time (cumulative duration of stenting of any type) during the 24-month study period. The safety outcome was device- or procedure-related serious adverse events during the full 24-month follow-up period. Stent migration rates were also evaluated.

Statistical Analysis

The hypothesis of the study was that the rate of stricture resolution for FCSEMS is non-inferior to MPS in patients with CP-associated BBS. An estimated 66% probability of stricture resolution was within the 95% confidence intervals determined in meta-analyses of studies of BBS outcomes after initial MPS^{5, 12, 13} or FCSEMS stent placement.¹⁴⁻¹⁷ The sample size was calculated for a one-sided 0.050 exact test using a noninferiority margin of 20%, where a *P* value < 0.05 would suggest that FCSEMS was non-inferior to MPS.¹⁸ For 80% power with a one-sided

5% significance level, allowing for 10% attrition during follow-up, a total of 164 patients were needed to draw non-inferiority conclusions with the defined level of certainty.

Data were summarized using descriptive statistics for continuous variables, including median with minimum and maximum or interquartile range (IQR), and frequency statistics for discrete variables and were tested for differences between the groups with a Mann-Whitney U test and a Fisher's exact test, respectively. Count variables, such as number of procedures/stents, were summarized using mean and standard deviation, and a negative binomial model was performed to test for differences between the groups. Statistical modeling was performed to identify clinical risk factors that might predict the primary and safety outcomes, namely age, male sex, time since CP diagnosis, alcohol as CP etiology, calcifying CP, being a surgical candidate, prior pancreatic plastic stent, baseline serum bilirubin level or gallbladder in situ. This modeling was performed using Cox proportional hazards techniques using exact ties. The primary outcome power calculation and *P* value were calculated using StatXact version 12; all other analyses were performed using SAS version 9.4. All analyses were considered significant if the *P* value was < 0.05.

In addition to the intention-to-treat analysis (ITT), as-treated analyses were also performed, with recognition of inherent biases for each analysis type.¹⁹ The as-treated study groups comprised patients who were treated with one type of stent throughout the study, namely treated with MPS only or with FCSEMS only, regardless of baseline randomization. This group was used to test differences in number of ERCs, number of stents placed, procedure duration, and total treatment time.

RESULTS

Enrollment was completed with 84 patients randomized to the MPS arm and 80 to the FCSEMS arm (**Figure 1**). No significant differences in baseline variables were found between both study arms in the ITT cohort (**Table 1**). Median baseline age was 52 years (range 26-74) and median years since first diagnosis of CP was 1.9 (range 0.1-35.8). At the time of randomization 43.9% (72/164) patients had a prior single plastic stent indwelling, median alkaline phosphatase level was 290.0 (range (46.0-1909.0)), and median bilirubin level was 1.3 (range 0.1-25.3) mg/dL, with similar values for each measure in both arms ($P = 0.755$, $P = 0.273$ and $P = 0.590$ respectively).

The as-treated study population comprised patients who were treated with one type of stent throughout the study. Of 138 patients included in the as-treated patient population, 60 patients treated with MPS and 53 patients treated with FCSEMS were eligible for analysis of the primary outcome 24 months after initial treatment.

Primary Outcome

Stricture resolution status at 24 months after randomization was 77.1% (54/70) in the MPS arm and 75.8% (47/62) in the FCSEMS arm ($P = 0.008$ for noninferiority) (**Figures 2-4**). The upper confidence limit for the difference in stricture resolution status suggested that the greatest amount by which the FCSEMS stricture resolution rate could be lower than that for MPS was 14.2%, which was within the noninferiority margin of 20%.

Of 31 patients who failed the primary endpoint (had no stricture resolution), 29 were restented and 2 had surgery. Univariate analysis showed that none of the predefined candidate clinical risk factors were associated with successful stricture resolution (P value range 0.09-0.91).

Secondary Outcomes

Technical success

Technical success of stent placement at baseline was 97.6% (82/84) for the MPS arm and 98.6% (79/80) for the FCSEMS arm ($P = 0.99$). Of 90 patients who had an FCSEMS at any point during the study, 72 underwent uneventful endoscopic removal in one procedure. Seven FCSEMS removals used a SEMS-in-SEMS removal technique²⁰ due to the presence of tissue overgrowth embedding the proximal, distal or both FCSEMS ends; this technique consisted of placement of an additional FCSEMS through the original FCSEMS aimed at inducing pressure necrosis of the hyperplastic tissue over the ends of the stent, followed in all cases by uneventful removal of both FCSEMS 9 to 121 days later. There were no reports of deficiencies in the covering of the FCSEMS in any of the 7 cases.

Number of ERCPs, number of stents and procedure duration, and treatment duration

In the ITT analysis, the mean number of ERCPs during 24 months after randomization, including the procedure during which the last stent(s) were removed, was 3.9 ± 1.3 in the MPS arm and 2.6 ± 1.3 in the FCSEMS arm ($P < 0.001$) (**Figure 2, Table 2**). Results were similar in the as-treated analysis (3.9 vs. 2.2 respectively, $P < 0.001$)

The mean total number of stents placed was 6.7 ± 4.4 in the MPS arm and 2.3 ± 3.3 in the FCSEMS arm ($P < 0.001$; **Figure 2, Table 2**) in the ITT analysis, reflecting crossover from FCSEMS to MPS and vice versa that led some patients to be treated with more than one type of stent during the course of the study, and additional FCSEMS used for SEMS-in-SEMS removal in 7 patients. In the as-treated analysis, the mean total number of stents placed was 7.0 ± 4.4 in the MPS arm and 1.3 ± 0.6 in the FCSEMS arm ($P < 0.001$).

Median stent placement procedure duration was similar between arms in the ITT analysis (28.0 vs. 26.0 minutes, $P=0.519$, **Table 2**) and trended lower for FCSEMS in the as-treated analysis (28.0 vs. 24.0, $P=0.062$). Median total treatment duration during the study (11.8 vs. 11.8 months for ITT, 11.8 vs. 11.7 for as-treated) were similar between arms (**Table 2**). The median treatment duration and mean study follow-up (23.7 months, IQR 22.8-24.4 months) closely matched the study plan. The median stent-free time (time from stent removal or observation of complete distal migration to restenting) was 360 days for MPS and 362 days for SEMS ($P = 0.957$). Among the 92 patients who had at least 1 plastic stent in place at some point during the study, a mean of 3.0 stents were placed during the final MPS procedure.

Safety Outcomes and Stent Migration

Stent- or procedure-related SAEs occurred in 16 (19.0%) MPS patients and 19 (23.8%) FCSEMS patients ($P = 0.568$) (**Figure 2**). There was no significant difference in rates of individual SAEs between arms (P value range 0.236-0.999 for comparisons) (**Table 3**). Among 16 patients who developed cholangitis/fever/jaundice (9 for MPS vs. 7 for FCSEMS), possible causes based on documented surrounding events were occlusion (4), migration (2), procedure-related (3) in the

MPS arm, and migration (5), occlusion (1) or removal (1) in the FCSEMS arm. Among 4 patients who developed cholecystitis (1 for MPS vs. 3 for FCSEMS), treatments included laparoscopic cholecystectomy in 1 MPS patient, and hospitalization (2) or outpatient medical treatment (1) in 3 FCSEMS patients. Other SAEs included abdominal pain (5 vs. 5), post-ERCP pancreatitis (0 vs. 2), acute-on-chronic pancreatitis (0 vs. 2) and perforation of the duodenum (1 vs. 0). There were no stent- or procedure-related deaths. Over the duration of follow-up, 11 patients (6.7%) were diagnosed with pancreatic cancer. Univariate analysis showed that the candidate clinical risk factors were not associated with stent- or procedure-related SAEs (P value range 0.15-0.86).

Overall, 18 (21.4%) MPS patients and 15 (18.8%) FCSEMS patients had at least one stent migration during the study, which was not significantly different between groups ($P = 0.701$, ITT analysis). The most frequent type of migration was complete distal migration (CDM; 11 patients in each group, $P = 0.999$, ITT), followed by partial distal (6 vs. 5 for MPS vs. FCSEMS, $P = 0.999$, ITT) and proximal migration (3 vs. 4, $P = 0.715$, ITT). Of 60 patients treated with MPS only during the study, 9 were observed to have CDM after a median of 101 days (IQR 86-141.5 days) after baseline or last MPS exchange. Of 53 patients treated with an FCSEMS only, 4 were observed to have CDM after a median of 339 days (IQR 324.5-344.5 days) after baseline, and 1 of those 4 was restented.

DISCUSSION

This open label, multicenter randomized noninferiority clinical trial demonstrated that in patients with CP-associated BBS, 12-month treatment with MPS vs. FCSEMS led to similar rates of

stricture resolution and adverse events, with fewer numbers of ERCPs over the 24-month study period in the FCSEMS arm.

CP-associated BBS is the most common non-surgery-related type of BBS, usually involving the distal third of the common bile duct as a late consequence of progressive fibrosis of the pancreatic parenchyma due to recurrent acute or chronic inflammation.^{21,22} Compared to BBS from other causes, CP-associated strictures may be more resistant to treatment because of the chronic nature of the insult and to the fibrotic nature of the strictures in calcifying CP.^{23,24} Uncovered SEMS is not an acceptable alternative to plastic stenting to treat BBS because of stent-associated endoluminal hyperplastic tissue ingrowth and difficulty of removal.²⁴ Thus, partially and fully covered SEMS have been studied despite their higher risk of stent migration compared to uncovered SEMS.²⁵ A systematic review of endotherapy for BBS reported respective clinical stricture resolution rates of 77% and 33% for covered SEMS (partially covered in 3 studies, fully covered in 9 studies) and plastic stents at 12 months of follow-up, while no difference was seen between the 2 methods for strictures related to liver transplant or other causes.²³ The rate of stricture resolution for FCSEMS in our trial is similar to this study, but our rate for MPS was substantially higher. This might reflect that our trial was conducted at centers with high levels of experience and high case volumes of endotherapy for the treatment of BBS secondary to CP, including the placement of MPS which can be technically challenging.

In contrast to several previous studies that used FCSEMS removal or exchange at 6 months or less,^{7, 12, 26, 27} our RCT evaluated 12-month FCSEMS indwell in patients with CP-associated BBS. We chose 12-month treatment duration because this was on the higher end of published

stent indwell duration, and because low stricture recurrence rates have been reported after 10-12 month FCSEMS indwell in the CP patient population.⁶ While longer duration of stent indwell has been associated with lower stricture recurrence,²⁸ the longer FCSEMS indwell time might also have led to a higher rate of SAEs and migration than seen in other studies. Rates of adverse events were higher for both FCSEMS and MPS (17.9% vs. 23.8%) in our study compared to the rate reported for BBS of any etiology in the previously mentioned systematic review (covered SEMS and PS groups 13% vs. 14%, 95% CI, 7%-19% vs. 8.1%-19%, $P = 0.9$).²³ We did not observe a lower rate of adverse events for FCSEMS compared to MPS as was seen in this systematic review. Approximately 20% of patients experienced stent migration within both arms of our study, which was somewhat higher than past single-arm studies of MPS (10.2%-13%)^{12, 13} and FCSEMS (5%-16.2%)^{14, 15, 17} that informed our statistical hypothesis. In 7 cases, FCSEMS removal failed with conventional techniques and required insertion of an inner FCSEMS to obtain pressure necrosis of the proximal and/or distal hyperplastic tissue embedding stent edges. Following FCSEMS removal, there were no reports of deficiencies in the covering of the FCSEMS in all the 7 cases, and tissue overgrowth was possibly related to the 12-month stent indwelling period.

Comorbidities further complicate CP treatment issues. Patients with CP are often poor surgical candidates because of malnutrition, which is associated with increased morbidity, a higher rate of infectious complications and longer ICU stay compared to well-nourished patients with CP who undergo pancreatic surgery.²⁹ Most patients develop chronic pain that is multifactorial, thought to be caused by parenchymal and ductal hypertension and parenchymal inflammation.³⁰ A meta-analysis reported that 5 years after diagnosis, CP patients have a nearly eight-fold increased risk

of pancreatic cancer.³¹ Consistent with this finding, 11 patients (6.7%) of the 164 patients who were randomized in our study were diagnosed with pancreatic cancer during follow-up.

Noncompliance is common among heavy alcohol users, and vigilant gastroenterological follow-up is necessary because of ongoing risks of severe complications in these patients. For example, a retrospective study of 14 patients with chronic alcoholic CP who had stent placement for biliary stenosis reported no complications in 2 patients who attended follow-up visits for stent exchanges, compared to 16 observations of cholangitis and 3 diagnoses of biliary sepsis among the remaining 12 patients, who were admitted a mean 2.9 times/patient as emergency cases.³²

Patients such as these could benefit from the lower frequency of stent exchanges with comparable efficacy and safety seen for FCSEMS compared to MPS in our study. The incidence of pancreatic cancer was similar in the 2 groups, thus we believe that the lower frequency of repeated cholangiograms did not affect the possibility for an earlier cancer diagnosis.

Importantly, before the start of long-term FCSEMS insertion to dilate a benign stricture, exhaustive investigations should be done to exclude an underlying malignancy.

Our study has several strengths and limitations. The randomized trial design ensured that the MPS and FCSEMS groups had similar distributions of clinical risk factors at baseline. Patients with past use of a metal stent or more than 1 plastic stent were excluded since their likelihood of stricture resolution could be lower due to ductal fibrosis at baseline. The study completion rate was high, with monitoring that continued for 1 year after the end of the 12-month treatment period. Limitations of the study included mis-randomization of 3 patients in each arm and crossover in 13% of patients during follow-up that might have altered the balance of baseline risk between arms. Data are not available on balloon dilation concurrent with stent placement at

the index procedure. Results may not be generalizable to less experienced endoscopists or community gastroenterology practices. The rates of stricture resolution by 12 months after stent removal should not be considered definitive, since strictures are known to recur late. For example, a longitudinal study of 118 patients with CP-associated BBS who received 10- to 12-month FCSEMS treatment reported that at a median of 58 months post-FCSEMS indwell, the probability of remaining stent-free was 61.6%,⁶ compared to approximately 75% for the FCSEMS arm at 1 year in the current trial that used the same device. This study was sponsored by the manufacturer of the metal stent used in the study.

In conclusion, endotherapy of BBS secondary to CP has similar effectiveness and safety when using a single FCSEMS compared to MPS for one year, with the FCSEMS option requiring fewer ERCPs over 2 years after initial stenting.

DATA SHARING

The data, analytic methods, and study materials for this study may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (<http://www.bostonscientific.com/en-US/data-sharing-requests.html>).

Figure 1. CONSORT diagram of patient enrollment, randomization and follow-up

Journal Pre-proof

BBS benign biliary stricture MPS multiple plastic stents

FCSEMS fully covered self-expanding metal stent COPD chronic obstructive pulmonary disease

Figure 2. Summary of main outcomes (ITT analysis)

ITT intention to treat SAE serious adverse event
ERCP endoscopic retrograde cholangiopancreatography MPS multiple plastic stents
FCSEMS fully covered self-expanding metal stent

* For stricture resolution, $P < 0.05$ suggests that FCSEMS is noninferior to MPS.

† For SAEs and number of ERCPs, $P < 0.05$ suggests different values for FCSEMS and MPS

**Number of ERCPs on an as-treated basis are 3.9 (MPS) and 2.2 (FCSEMS), $P < 0.001$

Figure 3. Common bile duct stricture secondary to chronic pancreatitis (a) (arrow, pancreatic calcifications). Five plastic stent (b) are inserted with complete stricture dilatation after stents removal (c). (Images courtesy of Policlinico A. Gemelli IRCCS)

Journal Pre-proof

Figure 4. Common bile duct stricture secondary to chronic pancreatitis (a) (arrow, pancreatic calcifications). Fully covered self-expandable metal stent is placed (b) obtaining stricture dilatation after metal stent removal (c). (Images courtesy of Policlinico A. Gemelli IRCCS)

Journal Pre-proof

REFERENCES

1. Costamagna G, Boskoski I. Current treatment of benign biliary strictures. *Ann Gastroenterol* 2013;26:37-40.
2. Deviere J, Nageshwar Reddy D, Puspok A, et al. Successful management of benign biliary strictures with fully covered self-expanding metal stents. *Gastroenterology* 2014;147:385-95; quiz e15.
3. Costamagna G. Covered self-expanding metal stents in benign biliary strictures: not yet a "new paradigm" but a promising alternative. *Gastrointest Endosc* 2008;67:455-7.
4. Issa Y, van Santvoort HC, Fockens P, et al. Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study. *HPB (Oxford)* 2017;19:978-985.
5. Draganov P, Hoffman B, Marsh W, et al. Long-term outcome in patients with benign biliary strictures treated endoscopically with multiple stents. *Gastrointest Endosc* 2002;55:680-6.
6. Lakhtakia S, Reddy N, Dolak W, et al. Long-term outcomes after temporary placement of a self-expanding fully covered metal stent for benign biliary strictures secondary to chronic pancreatitis. *Gastrointest Endosc* 2020;91:361-369 e3.
7. Haapamaki C, Kylanpaa L, Udd M, et al. Randomized multicenter study of multiple plastic stents vs. covered self-expandable metallic stent in the treatment of biliary stricture in chronic pancreatitis. *Endoscopy* 2015;47:605-10.
8. Dumonceau JM, Tringali A, Papanikolaou IS, et al. Endoscopic biliary stenting: indications, choice of stents, and results: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline - Updated October 2017. *Endoscopy* 2018;50:910-930.
9. Committee ASoP, Chandrasekhara V, Chathadi KV, et al. The role of endoscopy in benign pancreatic disease. *Gastrointest Endosc* 2015;82:203-14.
10. Committee ASoP, Chathadi KV, Chandrasekhara V, et al. The role of ERCP in benign diseases of the biliary tract. *Gastrointest Endosc* 2015;81:795-803.
11. Abdallah AA, Krige JE, Bornman PC. Biliary tract obstruction in chronic pancreatitis. *HPB (Oxford)* 2007;9:421-8.
12. Catalano MF, Linder JD, George S, et al. Treatment of symptomatic distal common bile duct stenosis secondary to chronic pancreatitis: comparison of single vs. multiple simultaneous stents. *Gastrointest Endosc* 2004;60:945-52.
13. Eickhoff A, Jakobs R, Leonhardt A, et al. Endoscopic stenting for common bile duct stenoses in chronic pancreatitis: results and impact on long-term outcome. *Eur J Gastroenterol Hepatol* 2001;13:1161-7.
14. Behm B, Brock A, Clarke BW, et al. Partially covered self-expandable metallic stents for benign biliary strictures due to chronic pancreatitis. *Endoscopy* 2009;41:547-51.
15. Kahaleh M, Behm B, Clarke BW, et al. Temporary placement of covered self-expandable metal stents in benign biliary strictures: a new paradigm? (with video). *Gastrointest Endosc* 2008;67:446-54.
16. Mahajan A, Ho H, Sauer B, et al. Temporary placement of fully covered self-expandable metal stents in benign biliary strictures: midterm evaluation (with video). *Gastrointest Endosc* 2009;70:303-9.
17. Park DH, Lee SS, Lee TH, et al. Anchoring flap versus flared end, fully covered self-expandable metal stents to prevent migration in patients with benign biliary strictures: a multicenter, prospective, comparative pilot study (with videos). *Gastrointest Endosc* 2011;73:64-70.

18. Chan IS. Exact tests of equivalence and efficacy with a non-zero lower bound for comparative studies. *Stat Med* 1998;17:1403-13.
19. Rehal S, Morris TP, Fielding K, et al. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. *BMJ Open* 2016;6:e012594.
20. Tringali A, Blero D, Boskoski I, et al. Difficult removal of fully covered self expandable metal stents (SEMS) for benign biliary strictures: the "SEMS in SEMS" technique. *Dig Liver Dis* 2014;46:568-71.
21. Familiari P, Boskoski I, Bove V, et al. ERCP for biliary strictures associated with chronic pancreatitis. *Gastrointest Endosc Clin N Am* 2013;23:833-45.
22. Ma MX, Jayasekeran V, Chong AK. Benign biliary strictures: prevalence, impact, and management strategies. *Clin Exp Gastroenterol* 2019;12:83-92.
23. Siiki A, Helminen M, Sand J, et al. Covered self-expanding metal stents may be preferable to plastic stents in the treatment of chronic pancreatitis-related biliary strictures: a systematic review comparing 2 methods of stent therapy in benign biliary strictures. *J Clin Gastroenterol* 2014;48:635-43.
24. Gupta R, Reddy DN. Stent selection for both biliary and pancreatic strictures caused by chronic pancreatitis: multiple plastic stents or metallic stents? *J Hepatobiliary Pancreat Sci* 2011;18:636-9.
25. Deviere J, Devaere S, Baize M, et al. Endoscopic biliary drainage in chronic pancreatitis. *Gastrointest Endosc* 1990;36:96-100.
26. Cahen DL, van Berkel AM, Oskam D, et al. Long-term results of endoscopic drainage of common bile duct strictures in chronic pancreatitis. *Eur J Gastroenterol Hepatol* 2005;17:103-8.
27. Cote GA, Slivka A, Tarnasky P, et al. Effect of Covered Metallic Stents Compared With Plastic Stents on Benign Biliary Stricture Resolution: A Randomized Clinical Trial. *JAMA* 2016;315:1250-7.
28. Khan MA, Baron TH, Kamal F, et al. Efficacy of self-expandable metal stents in management of benign biliary strictures and comparison with multiple plastic stents: a meta-analysis. *Endoscopy* 2017;49:682-694.
29. Schnellendorfer T, Adams DB. The effect of malnutrition on morbidity after Surgery for chronic pancreatitis. *Am Surg* 2005;71:466-72; discussion 472-3.
30. Strate T, Yekebas E, Knoefel WT, et al. Pathogenesis and the natural course of chronic pancreatitis. *Eur J Gastroenterol Hepatol* 2002;14:929-34.
31. Kirkegard J, Mortensen FV, Cronin-Fenton D. Chronic Pancreatitis and Pancreatic Cancer Risk: A Systematic Review and Meta-analysis. *Am J Gastroenterol* 2017;112:1366-1372.
32. Kiehne K, Folsch UR, Nitsche R. High complication rate of bile duct stents in patients with chronic alcoholic pancreatitis due to noncompliance. *Endoscopy* 2000;32:377-80.

Table 1. Baseline characteristics of patients (N=164)

Characteristic	Median (range) or % (x/n)		P value
	MPS (N=84)	FCSEMS (N=80)	
Median age (years)	53.0 (26.0,74.0)	51.0 (28.0,74.0)	0.176
Male	85.7% (72/84)	87.5% (70/80)	0.821
Median time since CP diagnosed (years)*	1.7 (0.1,32.4)	3.1 (0.1,35.8)	0.768
Gallbladder in situ	85.7% (72/84)	86.3% (69/80)	0.999
CP etiology alcoholic	67.9% (53/78)	76.1% (54/71)	0.282
Calcifying CP	77.5% (62/80)	79.7% (59/74)	0.845
Candidate for surgery	79.2% (61/77)	83.3% (60/72)	0.538
Prior plastic stent	45.2% (38/84)	42.5% (34/80)	0.755
Prior biliary sphincterotomy	47.6% (39/82)	49.4% (39/79)	0.875
Prior pancreatic sphincterotomy	32.9% (27/82)	32.9% (26/79)	0.999
Biliary or pancreatic sphincterotomy (prior or at baseline study procedure)	90.5% (76/84)	96.3% (77/80)	0.212
Median baseline bilirubin (mg/dL)*	1.4 (0.2,17.7)	1.0 (0.1,25.3)	0.590
Median baseline alkaline phosphatase (IU/L)*	262.5 (78) (55.0,1909.0)	337.0 (74) (46.0,1871.0)	0.273

MPS multiple plastic stents

FCSEMS fully covered self-expanding metal stent

CP chronic pancreatitis

*Median (n) (range) are shown if n < group N.

Table 2. Procedure characteristics for ITT and as-treated patient groups

Procedure characteristic	ITT			As-treated*		
	MPS	FCSEMS	P-value	MPS	FCSEMS	P value
Mean number of ERCPs [†]	3.9 ± 1.3 (82)	2.6 ± 1.3 (79)	<.001	3.9 ± 1.2 (69)	2.2 ± 0.9 (69)	<.001
Mean number of stents placed	6.7 ± 4.4 (81)	2.3 ± 3.3 (79)	<.001	7.0 ± 4.4 (69)	1.3 ± 0.6 (68)	<.001
Median procedure duration (min)	28.0 (302) (5.0,144.0)	26.0 (192) (3.0,182.0)	0.519	28.0 (254) (5.0,182.0)	24.0 (143) (3.0,120.0)	0.062
Median total stenting time (months)	11.8 (80) (0.1,25.4)	11.8 (79) (0.1,25.3)	0.975	11.8 (68) (0.1,23.6)	11.7 (68) (0.1,25.0)	0.845

ITT intention to treat MPS multiple plastic stents FCSEMS fully covered self-expanding metal stent

* "As-treated" refers to patients who were treated with one type of stent throughout the study.

Mean ± SD or median (no. of procedures) (range) are shown.

[†] Includes stent removal procedures

Table 3. Patients with at least one device- or removal-related serious adverse event, or stent migration (ITT analysis, N=164)

Serious adverse event (SAE)	MPS (N=84)	FCSEMS (N=80)	P value
Any SAE	19.0% (16/84)	23.8% (19/80)	0.568
Abdominal pain	6.0% (5/84)	6.3% (5/80)	0.999
Cholangitis/fever/jaundice	10.7% (9/84)	8.8% (7/80)	0.794
Cholecystitis (among patients with a gallbladder)	1.4% (1/72)	4.3% (3/69)	0.359
Post-ERCP pancreatitis*	0.0% (0/84)	2.5% (2/80)	0.236
Acute-on-chronic pancreatitis	0.0% (0/84)	2.5% (2/80)	0.236
Perforation of duodenum	1.2% (1/84)	0.0% (0/80)	0.999
Post-sphincterotomy bleed (among patients who had a sphincterotomy)	0.0% (0/76)	1.3% (1/77)	0.999
Other SAE [†]	2.4% (2/84)	2.5% (2/80)	0.999
Stent migration	21.4% (18/82)	18.8% (15/80)	0.701

ITT intention to treat

MPS multiple plastic stents

FCSEMS fully covered self-expanding metal stent

ERCP endoscopic retrograde cholangiopancreatography

* 1 had prior biliary sphincterotomy, and 1 had biliary sphincterotomy at time of procedure

[†] Other SAEs for MPS: recurrent cholestasis, mobile cholelithiasis; for FCSEMS: bacterial blood infection, duodenal edema

Journal Pre-proof

Enrollment

Excluded (n= 8)

- 3 – prior biliary metal or ineligible plastic stenting
- 2 – obstructive biliary symptoms from acute pancreatitis
- 1 – BBS etiology not chronic pancreatitis
- 1 – stricture within 2 cm of common bile duct bifurcation
- 1 – declined

Randomized (n= 164)

Randomization and Treatment

Randomized to MPS (n= 84)

- ◆ Received MPS (n= 81)
- ◆ Received FCSEMS (n= 3)

Randomized to FCSEMS (n= 80)

- ◆ Received FCSEMS (n= 77)
- ◆ Received MPS (n= 3)

Follow-up

14 ineligible for primary endpoint follow-up

- 5 – new diagnosis of pancreatic cancer, 2 died
- 5 – lost to follow-up
- 2 – failed stent placement
- 1 – withdrawn before stent placement
- 1 – no longer able to have endotherapy due to duodenal stenosis


18 ineligible for primary endpoint follow-up

- 6 – new diagnosis of pancreatic cancer
- 5 – lost to follow-up
- 5 – deaths from cause unrelated to stent
 - COPD exacerbation
 - sepsis
 - respiratory tract infection
 - suicide
 - unknown
- 1 – failed stent placement
- 1 – no longer able to have endotherapy due to duodenal stenosis


Primary Endpoint Analysis to 24 Months

Analyzed (n= 70)

Analyzed (n= 62)




A




B



C



A



B



C



Fully Covered Self-Expanding Metal Stent versus Multiple Plastic Stents to Treat Benign Biliary Strictures Secondary to Chronic Pancreatitis: A Multicenter Randomized Trial

WHAT YOU NEED TO KNOW

BACKGROUND AND CONTEXT

Endotherapy using multiple plastic stents (MPS) or a fully covered self-expanding metal stent (FCSEMS) can be used to treat benign biliary strictures (BBS) secondary to chronic pancreatitis (CP). A multicenter, international randomized trial was conducted to test whether FCSEMS was noninferior to MPS to treat patients with CP-associated BBS with signs or symptoms of biliary obstruction.

NEW FINDINGS

Eighty-four patients with CP-associated BBS were randomized to 12-month treatment with MPS and 80 were randomized to 12-month treatment with a single FCSEMS. After 12 months of post-treatment follow-up, patients treated with MPS had similar rates of stricture resolution and serious adverse events, and a higher mean number of endoscopic retrograde cholangiopancreatography (ERCP) procedures and mean number of stents placed, compared to patients treated with FCSEMS.

LIMITATIONS

Eleven patients crossed over from MPS to FCSEMS, and 10 from FCSEMS to MPS.

IMPACT

For patients with CP-associated BBS, similar efficacy and safety were seen for 12-month treatment using MPS compared to a single FCSEMS, with FCSEMS requiring fewer ERCPPs over 2 years.

LAY SUMMARY

For benign biliary stricture secondary to chronic pancreatitis, 12-month endotherapy using a single fully covered self-expandable metal stent has similar efficacy and safety and requires fewer procedural interventions than multiple plastic stents.